Progyny, Inc. (PGNY)
NASDAQ:PGNY
Want to see PGNY full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.33Last Year’s EPS
0.19Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized multiple operational and financial strengths: record Q1 revenue (at the high end of guidance), beats on net income/EPS/adjusted EBITDA, expanded gross margins, strong cash generation, completed a $200M buyback, and a de-risked renewal season with pipeline and early commitments pacing ahead of last year. Management raised full-year profitability guidance and maintained utilization and ART consumption assumptions. Challenges noted—administrative eligibility true-ups, ongoing investments (higher CapEx), comparability headwinds from a transition client, and conservative assumptions to guard against potential variability—are being actively managed and appear incremental rather than existential. Given the balance of robust financial results, validated clinical outcomes, and proactive mitigation of operational issues, the overall tone is constructive.Company Guidance
Record Q1 Revenue and Beat on Key Profitability Metrics
Reported record first-quarter revenue at the higher end of expectations; net income, EPS, and adjusted EBITDA all came in above guidance ranges. Reported revenue growth was +1.4% year-over-year, and growth was >12% when excluding the large former client under a transition-of-care agreement.
Raised Full-Year Profitability Guidance
Management increased full-year expectations for adjusted EBITDA, net income, and EPS. Full-year adjusted EBITDA guide is $232M–$244M; net income guide is $103.7M–$112.3M; diluted EPS guide is $1.23–$1.34 and adjusted EPS is $1.98–$2.09 (approximately 84M fully diluted shares).
Q2 and Full-Year Revenue Guidance with Strong Ex-Transition Growth
Q2 revenue guidance of $342M–$355M (growth 2.7%–6.6% reported; 8.3%–12.4% excluding the $17.2M transition client). Full-year revenue guidance $1.365B–$1.405B (growth 5.9%–9.0% reported; 10.1%–13.3% excluding the $48.5M transition client).
Healthy Member Engagement and Utilization
Management reported continued healthy member engagement with utilization trending to the high end of historical range. Full-year utilization assumption maintained at 1.04%–1.05% and ART cycle consumption per female unique maintained at 0.93–0.95.
Improved Margins and Profitability Resilience
Gross margin expanded and adjusted EBITDA margin remained healthy despite ongoing investments to expand platform capabilities. Efficiencies and lower stock compensation expense contributed to margin improvement and were expected to be recurring.
Strong Cash Generation, Working Capital and Balance Sheet
Generated approximately $446M in operating cash flow (noted alongside over $200M on a trailing twelve-month basis), maintained $225M in cash, cash equivalents and marketable securities, total working capital $266M, no borrowings on $200M revolver, and no debt.
Share Repurchases and Capital Return
Repurchased >5.5M shares for ~$116M during the quarter and completed the $200M repurchase program with ~8.8M shares repurchased in aggregate; board evaluating a potential new repurchase program.
Sales Pipeline Momentum and Renewal De-risking
Pipeline and early commitments pacing substantially ahead of a year ago; early favorable renewal notifications from some largest clients reduced remaining renewal exposure to the lowest level at this point relative to prior years. Encouraging activity with Cigna channel and aggregators for Progyny Select.
Third-Party Client Outcomes Study Validating Value
A third-party analysis by a large client showed improved clinical outcomes and cost savings over an eight-year period vs. pre-Progyny: increased fertility-related pregnancies per year, doubled pregnancy effectiveness per treatment, reduced multiples and miscarriage rates, more than halved preterm delivery rate, and lowered average cost per baby and NICU costs—demonstrating member experience, improved health outcomes and cost avoidance.
PGNY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PGNY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $19.16 | $23.72 | +23.80% |
Feb 26, 2026 | $22.25 | $17.69 | -20.49% |
Nov 06, 2025 | $18.01 | $22.37 | +24.21% |
Aug 07, 2025 | $23.06 | $22.85 | -0.91% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Progyny, Inc. (PGNY) report earnings?
Progyny, Inc. (PGNY) is schdueled to report earning on Jul 30, 2026, After Close (Confirmed).
What is Progyny, Inc. (PGNY) earnings time?
Progyny, Inc. (PGNY) earnings time is at Jul 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PGNY EPS forecast?
PGNY EPS forecast for the fiscal quarter 2026 (Q2) is 0.33.